Alaa Altahan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6623241/publications.pdf

Version: 2024-02-01

		1684188	1474206	
10	207	5	9	
papers	citations	h-index	g-index	
10	10	10	474	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Mutant <i>PPM1D</i> - and <i>TP53</i> -Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. JCO Precision Oncology, 2022, 6, e2100309.	3.0	15
2	CIN or not: An approach to the evaluation and management of chronic idiopathic neutrophilia. Blood Reviews, 2021, 46, 100739.	5.7	2
3	Severe Hemolysis in a COVID-19 Patient with Paroxysmal Nocturnal Hemoglobinuria. Case Reports in Hematology, 2021, 2021, 1-6.	0.4	6
4	Impact of margin status on survival after radical nephrectomyÂfor renal cell carcinoma. Journal of Surgical Oncology, 2021, 123, 687-692.	1.7	3
5	Association Between Pesticide Use and Incidence of Diffuse Large B-Cell Lymphoma. Anticancer Research, 2020, 40, 5423-5426.	1.1	3
6	KDM5A Regulates a Translational Program that Controls p53 Protein Expression. IScience, 2018, 9, 84-100.	4.1	25
7	Age-Related Chromosomal Aberrations in Patients with Diffuse Large B-Cell Lymphoma: An In Silico Approach. World Journal of Oncology, 2018, 9, 97-103.	1.5	1
8	Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. Cancer Research, 2017, 77, 4626-4638.	0.9	42
9	Estrogen receptor- $\hat{l}\pm$ directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15172-15177.	7.1	110
10	Evaluation of ciclopirox efficacy in rhabdomyosarcoma Journal of Clinical Oncology, 2014, 32, 10059-10059.	1.6	0